Masahiko Hayakawa, Ph.D.
Dr. Hayakawa has led research activities in the field of oncology and urology, creating multiple clinical and launched products. In 2012, he moved to the planning department and participated in strategy planning for Astellas’ research division. He assumed the Executive Director role in Modality Management in 2018. He has been in his present position since 2019.
Message from Unit Head
Our goal is to deliver new therapeutic options to patients suffering from cancers that have been difficult to treat with conventional drug therapies. We will continue our efforts to contribute to the future of cancer patients and their families.